 |
|
Gladstone researchers identify new drug target for Alzheimer's disease
December 02, 2005Researchers at the Gladstone Institute of Neurological Disease have identified a potential new way to stop brain cell death related to Alzheimer's disease.
Working with cell cultures, the scientists investigated how amyloid beta proteins, which build up in the brain tissue of people with Alzheimer's disease, kill neurons. The cell cultures were established from brain tissue of laboratory rats. Study findings showed that amyloid beta could be prevented from causing neuronal cell death with a compound called resveratrol, which is also found as a natural ingredient in red wine.
"Our study suggests that resveratrol and related compounds may protect against neuronal loss associated with Alzheimer's disease," explains senior author Li Gan, PhD, a staff research investigator at the Gladstone Institute of Neurological Disease and an assistant professor of neurology at UC San Francisco. "This could certainly open up new avenues for drug development."
The research results are reported in the December 2 issue of the Journal of Biological Chemistry.
According to the research team, it was particularly interesting that the beneficial effect of resveratrol was not due to a direct impact on amyloid beta or on neurons but rather on other types of brain cells, called microglia.
Microglia are the immune cells of the brain. They can protect or hurt neurons, depending on which of their powerful defense or attack pathways are activated. The investigators found that amyloid beta triggers a pathway in microglia that makes them attack neurons with poisonous chemicals. A key mediator in this pathway is a protein called NF-kB, which resveratrol happens to block. Without resveratrol, amyloid beta activates NF-kB in microglia, turning them into powerful neuron killing machines. Researchers found that, in the presence of resveratrol or of other molecules that blocked NF-kB, microglia were well behaved, and amyloid beta was unable to harm the neurons.
The study thus pinpoints NF-ÙB as an important contributor to the destructive power of amyloid beta, making it a key drug target, and it singles out resveratrol as holding the most promise for therapeutic intervention.
Gladstone Institutes
The research results are reported in the December 2 issue of the Journal of Biological Chemistry.
According to the research team, it was particularly interesting that the beneficial effect of resveratrol was not due to a direct impact on amyloid beta or on neurons but rather on other types of brain cells, called microglia.
Microglia are the immune cells of the brain. They can protect or hurt neurons, depending on which of their powerful defense or attack pathways are activated. The investigators found that amyloid beta triggers a pathway in microglia that makes them attack neurons with poisonous chemicals. A key mediator in this pathway is a protein called NF-kB, which resveratrol happens to block. Without resveratrol, amyloid beta activates NF-kB in microglia, turning them into powerful neuron killing machines. Researchers found that, in the presence of resveratrol or of other molecules that blocked NF-kB, microglia were well behaved, and amyloid beta was unable to harm the neurons.
The study thus pinpoints NF-ÙB as an important contributor to the destructive power of amyloid beta, making it a key drug target, and it singles out resveratrol as holding the most promise for therapeutic intervention.
Gladstone Institutes
Alzheimer Disease Current Events and Alzheimer Disease News RSSDelirium in hospitalized adults: Situation critical, no relief available
Every year as many as seven million adults in the United States experience delirium during hospitalization.
New data demonstrate potential for early detection of Alzheimer's disease
Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease.
Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis
A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH).
Measuring brain atrophy in patients with mild cognitive impairment
Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease.
Commonly used medications may produce cognitive impairment in older adults
Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults.
Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease
In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.
New test for mysterious metabolic diseases developed at Stanford/Packard
Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism.
Recalibrating 'fight or flight'
A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology
Vitamin B does not slow cognitive decline in Alzheimer's
A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease.
Protecting patient privacy the new fashioned way
Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act.
More Alzheimer Disease Current Events and Alzheimer Disease News Articles
 |
A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier by Patricia R. Callone (Editor) Written for patients, their families, and caregivers, the practical information here will help readers understand what is physically happening to the brain so they can empower their own special skills and talents throughout the disease process. The book is divided into three sections that correspond to the progression of Alzheimer’s, and the unique challenges encountered at each stage. *Section A: The four stages of Alzheimer's with hundreds of practical tips for coping at each level *Section B: Q&A for caregivers, including legal and financial issues, medication, helping children understand, handling the holidays and more. *Section C: Resources and websites. This is an essential book for all those who want to focus on the capabilities that... |
 |
Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease by Joanne Koenig Coste (Author), Robert Butler (Foreword) More than four million Americans suffer from Alzheimer’s, and as many as twenty million have close relatives or friends with the disease. Revolutionizing the way we perceive and live with Alzheimer’s, Joanne Koenig Coste offers a practical approach to the emotional well-being of both patients and caregivers that emphasizes relating to patients in their own reality. Her accessible and comprehensive method, which she calls habilitation, works to enhance communication between carepartners and patients and has proven successful with thousands of people living with dementia. Learning to Speak Alzheimer’s also offers hundreds of practical tips, including how to · cope with the diagnosis and adjust to the disease’s progression · help the patient talk about the illness · face the... |
 |
Alzheimer's Disease: Facing the Facts Starring: n/a Directed By: n/a Studio: Wgbh Wholesale Release Date: 03/17/2009 Run time: 56 minutes |
 |
The Alzheimer's Action Plan: What You Need to Know--and What You Can Do--about Memory Problems, from Prevention to Early Intervention and Care by P. Murali Doraiswamy M.D. (Author), Lisa P. Gwyther M.S.W. (Author), Tina Adler (Author) What would you do if your mother was having memory problems? |
 |
My Journey into Alzheimer's Disease by Robert Davis (Author) A book of encouragement of how one man of faith faced the oncoming darkness of Alzheimer's disease. In a powerful story of courage and faith, Davis shows how God gives strength and grace. |
|
Journal of Alzheimers Disease by Ios Press | |
 |
Doing Things: A Guide to Programing Activities for Persons with Alzheimer's Disease and Related Disorders by Jitka M. Zgola (Author) Doing Things shows how to provide a positive environment for persons with Alzheimer's disease by offering opportunities for social interaction and constructive, enjoyable activities. Zgola outlines the ways in which a patient's functional impairment can be assessed; the strengths, weaknesses, and needs most commonly encountered among persons with Alzheimer's disease; and ways activities can be tailored to accommodate them. She offers step-by-step instructions for selecting and presenting appropriate activities and includes cooking and crafts projects, a sample exercise routine, and a sample daily schedule. The techniques she describes are designed to promote a sense of security and self-esteem, by avoiding possible sources of confusion or confrontation. Based on the highly... |
![Trouble in Mind: Alzheimer's Disease [VHS]](http://ecx.images-amazon.com/images/I/41VJXB4JBHL._SL160_.jpg) |
Trouble in Mind: Alzheimer's Disease [VHS] Starring: Kate Jackson |
|
Mayo Clinic Guide Alzheimer's Disease by Clinic Mayo (Author) The essential resource for treatment, coping and caregiving for Alzheimer's.2 | |
 |
The Family Guide to Alzheimer's Disease: 5 Volume Set Starring: Leeza Gibbons Directed By: Mike Merryman For many families, Alzheimer's means a gradually diminishing quality of life both for the sufferer and caregivers. All too often, the disease has led to isolation and even a certain social stigma. It can impose psychological and emotional burdens just as heavy as the physical one. The Family Guide to Alzheimer's Disease was created to help families understand what to expect; deal effectively with the challenge of this disease; help their loved ones meet each day more successfully; and enhance the quality of life for all involved. |
| © 2009 BrightSurf.com |